Skip to content

Altamira Therapeutics Ltd.

CYTOF

CIK 0001601936

← back to feed
Revenue (TTM)
305.62K
+378.4% YoY Q2 Jun 2025
Net Income (TTM)
−8.2M
−23.6% YoY Q2 Jun 2025
EPS Diluted (TTM)
−2.99
+65.9% YoY Q2 Jun 2025
Gross Margin
-372.4%
Q2 Jun 2025
Operating Margin
-2,241.7%
Q2 Jun 2025
Net Margin
-2,683.2%
Q2 Jun 2025
Free Cash Flow (TTM)
—
Q2 Jun 2025
Cash
3.76K
Q2 Jun 2025
Total Debt
523.92K
Q2 Jun 2025
Shares Outstanding
4.66M sh
Q2 Jun 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings